维布妥昔单抗联合吉西他滨治疗复发或难治性外周T细胞淋巴瘤:一项LYSA二期研究
该二期研究评估维布妥昔单抗(BV)联合吉西他滨(GBV)诱导后BV维持治疗复发或难治性外周T细胞淋巴瘤的疗效。71例患者中,4周期诱导后总缓解率为46.5%,完全缓解率19.7%。中位随访32.6个月,中位缓解持续时间15.8个月,无进展生存期4.5个月,总生存期12.9个月。
要点
- 4周期GBV诱导后总缓解率46.5%,完全缓解率19.7%。
- 诱导期≥10%的3-4级不良事件包括中性粒细胞减少55%、贫血21%、血小板减少14%、感染14%。
- 基线可溶性CD30高与缓解和生存负相关,在TFHL和PTCL-NOS中尤为明显。
核心结论
- GBV方案在复发或难治性外周T细胞淋巴瘤中显示疗效,ALCL中较高,TFHL和PTCL-NOS组亦存在疗效。
- 基线可溶性CD30高与缓解和生存负相关,在TFHL和PTCL-NOS患者中似高度相关。
研究设计与样本
- LYSA二期研究,纳入经免疫组化CD30+细胞至少5%的复发或难治性外周T细胞淋巴瘤患者。
- 患者接受4周期GBV诱导(28天周期:吉西他滨1000 mg/m2第1、15天,BV 1.8 mg/kg第8天),缓解者后续最多12周期BV维持(21天周期)。
- 主要终点为4周期诱导后基于计算机断层扫描的Lugano标准评估的总缓解率。
- 共入组71例患者,中位年龄66岁,80.3%接受过1线既往治疗,60.6%为难治性。
主要发现
- 意向性分析中总缓解率为46.5%,完全缓解率19.7%。
- 28例患者接受了维持治疗。
- 诱导期≥10%的3-4级不良事件包括中性粒细胞减少55%、血小板减少14%、贫血21%、感染14%;维持期包括中性粒细胞减少39%、血小板减少21%、外周神经病变14%。
- 中位随访32.6个月,中位缓解持续时间15.8个月,中位无进展生存期4.5个月,中位总生存期12.9个月。
- 病理中心复核诊断:滤泡辅助T细胞淋巴瘤(TFHL)47.9%,间变性大细胞淋巴瘤(ALCL)ALK阴性19.7%、ALK阳性7%,外周T细胞淋巴瘤非特指型(PTCL-NOS)12.7%,其他类型12.7%。
关键数值与推荐
- 入组标准:经免疫组化CD30+细胞至少5%。
- 诱导方案:吉西他滨1000 mg/m2(第1、15天)联合BV 1.8 mg/kg(第8天),28天周期,共4周期。
- 维持方案:BV维持21天周期,最多12周期。
- 主要终点:4周期诱导后基于计算机断层扫描的Lugano标准评估的总缓解率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aim to evaluate the efficacy of brentuximab vedotin (BV) combined with gemcitabine (GBV) followed by BV maintenance in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL). Patients with at least 5% CD30+ cells by immunohistochemistry received 4 GBV induction (28 days) cycles of gemcitabine 1000 mg/m2 (day 1, day 15) plus BV 1.8 mg/kg (day 8) followed, in responding patients, by up to 12 BV maintenance (21 day) cycles. Primary end point was overall response rate (ORR) after 4 induction cycles by computed tomography scan-based Lugano criteria. Of 71 enrolled patients (median age of 66 years), 80.3% had received 1 previous line and 60.6% were refractory. The diagnoses per pathology central review were follicular helper T-cell lymphomas (TFHL; 47.9%), anaplastic large-cell lymphomas (ALCL; anaplastic lymphoma kinase [ALK] negative [19.7%] and ALK+ [7%]), peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS; 12.7%), and other entities (12.7%). In the intention-to-treat analysis, ORR was 46.5%, with 19.7% complete response. Twenty-eight patients received maintenance. Grade 3 to 4 adverse events reported in ≥10% of patients during induction comprised neutropenia (55%), thrombocytopenia (14%), anemia (21%), and infection (14%); during maintenance comprised neutropenia (39%), thrombocytopenia (21%), and peripheral neuropathy (14%). With a median follow-up of 32.6 months, the median duration of response, progression-free, and overall survival were 15.8, 4.5, and 12.9 months, respectively. Efficacy, higher in ALCL, was present in the TFHL and PTCL-NOS group. A negative association of high baseline soluble CD30 on both response and survival was found, which, in ad hoc analysis, appeared highly relevant in patients with TFHL and PTCL-NOS. This trial was registered at the European Union Drug Regulating Authorities Clinical Trials database as #2017-000409-1, and at www.clinicaltrials.gov as #NCT03496779.
引用
- Tournilhac O, Bouabdallah K, Lecolant S, et al. Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study. Blood Adv. 2025. PMID: 40758949. doi:10.1182/bloodadvances.2024015787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。